Complete financial analysis of Cara Therapeutics, Inc. (CARA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cara Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- New Provenance Everlasting Holdings Limited (2326.HK) Income Statement Analysis – Financial Results
- Jardine Cycle & Carriage Limited (JCYGY) Income Statement Analysis – Financial Results
- GUD Holdings Limited (GUDDY) Income Statement Analysis – Financial Results
- China Ruyi Holdings Limited (0136.HK) Income Statement Analysis – Financial Results
- Schindler Holding AG (0QOT.L) Income Statement Analysis – Financial Results
Cara Therapeutics, Inc. (CARA)
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.97M | 41.87M | 23.03M | 135.08M | 19.89M | 13.47M | 911.00K | 86.00K | 3.80M | 3.18M | 11.96M | 1.19M | 0.00 |
| Cost of Revenue | 6.17M | 7.27M | 1.55M | 107.07M | 113.16M | 75.53M | 48.52M | 49.25M | 21.22M | 15.07M | 8.69M | 1.92M | 0.00 |
| Gross Profit | 14.79M | 34.60M | 21.47M | 28.01M | -93.28M | -62.06M | -47.61M | -49.17M | -17.42M | -11.89M | 3.28M | -731.00K | 0.00 |
| Gross Profit Ratio | 70.56% | 82.65% | 93.25% | 20.74% | -469.06% | -460.78% | -5,226.45% | -57,170.93% | -458.01% | -374.28% | 27.41% | -61.43% | 0.00% |
| Research & Development | 108.51M | 91.88M | 82.70M | 107.85M | 113.82M | 75.53M | 48.52M | 49.25M | 21.22M | 15.07M | 8.69M | 4.60M | 7.16M |
| General & Administrative | 27.65M | 30.26M | 29.41M | 21.75M | 17.75M | 15.32M | 11.87M | 9.23M | 7.77M | 6.18M | 3.52M | 2.83M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.65M | 30.26M | 29.41M | 21.75M | 17.75M | 15.32M | 11.87M | 9.23M | 7.77M | 6.18M | 3.52M | 2.83M | 2.41M |
| Other Expenses | 0.00 | 2.06M | 642.00K | 97.00K | 4.49M | 2.98M | 1.16M | 652.00K | 101.00K | 361.00K | 0.00 | 0.00 | -180.00K |
| Operating Expenses | 136.29M | 122.14M | 112.11M | 129.70M | 131.57M | 90.85M | 60.40M | 58.49M | 28.99M | 21.25M | 12.20M | 7.43M | 9.57M |
| Cost & Expenses | 142.46M | 129.40M | 112.11M | 129.70M | 131.57M | 90.85M | 60.40M | 58.49M | 28.99M | 21.25M | 12.20M | 7.43M | 9.57M |
| Interest Income | 0.00 | 2.06M | 603.00K | 2.06M | 4.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 604.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 126.00K | 3.76M | 0.00 | 0.00 |
| Depreciation & Amortization | 259.00K | 1.67M | 1.55M | 1.01M | 799.00K | 370.00K | 495.00K | 1.47M | 839.00K | 783.00K | 789.00K | 1.02M | 1.17M |
| EBITDA | -117.65M | -83.80M | -88.19M | 5.59M | -111.48M | -77.01M | -58.99M | -56.94M | -24.35M | -17.29M | 552.00K | -5.22M | -8.58M |
| EBITDA Ratio | -561.09% | -209.08% | -386.85% | 4.14% | -561.60% | -574.52% | -6,529.64% | -67,906.98% | -662.32% | -568.84% | -1.98% | -438.24% | 0.00% |
| Operating Income | -121.50M | -87.54M | -89.08M | 5.39M | -111.68M | -77.38M | -59.49M | -58.40M | -25.19M | -18.07M | -237.00K | -6.24M | -9.57M |
| Operating Income Ratio | -579.43% | -209.08% | -386.85% | 3.99% | -561.60% | -574.52% | -6,529.64% | -67,906.98% | -662.32% | -568.84% | -1.98% | -524.03% | 0.00% |
| Total Other Income/Expenses | 2.98M | 2.06M | 642.00K | 2.33M | 4.49M | 2.98M | 1.16M | 652.00K | 101.00K | 126.00K | -3.76M | -66.00K | -275.00K |
| Income Before Tax | -118.51M | -85.47M | -88.44M | 7.72M | -107.19M | -74.40M | -58.33M | -57.75M | -25.09M | -17.95M | -3.99M | -6.30M | -9.84M |
| Income Before Tax Ratio | -565.21% | -204.16% | -384.06% | 5.71% | -539.02% | -552.39% | -6,402.74% | -67,148.84% | -659.66% | -564.87% | -33.38% | -529.58% | 0.00% |
| Income Tax Expense | 0.00 | -2.06M | -248.00K | -691.00K | -816.00K | -389.00K | -204.00K | -468.00K | -397.00K | -201.00K | -30.00K | -31.00K | -35.00K |
| Net Income | -118.51M | -83.41M | -88.19M | 8.41M | -106.37M | -74.01M | -58.13M | -57.28M | -24.69M | -17.75M | -3.96M | -6.27M | -9.81M |
| Net Income Ratio | -565.21% | -199.23% | -382.98% | 6.23% | -534.91% | -549.51% | -6,380.35% | -66,604.65% | -649.22% | -558.55% | -33.12% | -526.97% | 0.00% |
| EPS | -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.18 | -1.01 | -1.59 |
| EPS Diluted | -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.18 | -1.01 | -1.59 |
| Weighted Avg Shares Out | 54.15M | 53.65M | 50.72M | 47.41M | 42.67M | 35.89M | 31.20M | 27.28M | 24.62M | 20.88M | 21.84M | 6.18M | 6.18M |
| Weighted Avg Shares Out (Dil) | 54.15M | 53.65M | 50.72M | 47.92M | 42.67M | 35.89M | 31.20M | 27.28M | 24.62M | 20.97M | 21.84M | 6.18M | 6.18M |
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva
3 Small-Cap Stocks to Sell in June Before They Crash and Burn
Cara Therapeutics to Present at the Jefferies Healthcare Conference
7 Stocks With 1,000% Upside Potential
Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call Transcript
Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
Source: https://incomestatements.info
Category: Stock Reports